Despite its great promise, personalized oncology still faces many hurdles, and it is
increasingly clear that targeted drugs and molecular biomarkers alone yield only modest …

We review the evolution, achievements, and limitations of the current paradigm shift in
medicine, from the “one‐size‐fits‐all” model to “Precision Medicine.” Precision, or …

Despite a growing body of knowledge on the mechanisms underlying the onset and
progression of cancer, treatment success rates in oncology are at best modest. Current …

Efforts to personalize medicine in oncology have been limited by reductive characterizations
of the intrinsically complex underlying biological phenomena. Future advances in …

The amount of “big” data generated in clinical oncology, whether from molecular, imaging,
pharmacological, or biological origin, brings novel challenges. To mine efficiently this source …

The amount of'big'data generated in clinical oncology, whether from molecular, imaging,
pharmacological or biological origin, brings novel challenges. To mine efficiently this source …

There is a need for new approaches and endpoints in oncology drug development,
particularly with the advent of immunotherapies and the multiple drug combinations under …

In this paper, we review multiscale modeling for cancer treatment with the incorporation of
drug effects from an applied system's pharmacology perspective. Both the classical …

Cancers present with high variability across patients and tumors; thus, cancer care, in terms
of disease prevention, detection, and control, can highly benefit from a personalized …

Forecasting future trends in observable phenomena is of great interest to many disciplines.
Methods and models that are able to predict future outcomes have a variety of applications …